IL-6 is a critical driver of acute and chronic inflammation and has been reported to act as a T cell survival factor. The influence of IL-6 on T cell homeostasis is not well resolved. We demonstrate that IL-6 signaling drives T cell expansion under inflammatory conditions but not during normal homeostasis. During inflammation, IL-6Rα–deficient T cells are unable to effectively compete with wild type T cells. IL-6 promotes T cell proliferation, and this is associated with low-level expression of the RORγt transcription factor. T cells upregulate Rorc mRNA at levels substantially diminished from that seen in Th17 cells. Blockade of RORγt through genetic knockout or a small molecule inhibitor leads to T cell expansion defects comparable to those in IL-6Rα–deficient T cells. Our results indicate that IL-6 plays a key role in T cell expansion during inflammation and implicates a role for the transient induction of low-level RORγt.

Interleukin-6 is a pleiotropic cytokine that is a key mediator of the acute phase response and facilitates inflammatory responses (13). It is produced by T cells, B cells, macrophages, dendritic cells, and stromal and epithelial cells (4). Although physiologic levels of serum IL-6 are normally low, IL-6 is rapidly induced in monocytes upon recognition of TLR agonists such as LPS (5, 6). Elevated IL-6 levels have been found in patients with rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease, and other chronic inflammatory disorders (79).

The IL-6 receptor is a heterodimer formed by IL-6Rα (CD126) and the shared cytokine receptor gp130 (CD130) (10). Upon binding to IL-6, IL-6Rα forms a complex with gp130 that initiates signal transduction (11). IL-6Rα itself has no intrinsic signaling capacity, whereas gp130 activates JAK kinases and induces STAT1 and STAT3 phosphorylation (12, 13). Whereas gp130 is ubiquitously expressed, IL-6Rα expression is restricted to hepatocytes, megakaryocytes, and subsets of leukocytes, including dendritic cells, macrophages, and T cells (14, 15). IL-6Rα is highly expressed on naive T cells (16) and IL-6 signaling drives the differentiation of Th17 T cells, a T helper subset characterized by the production of IL-17A (1719). Retinoic acid–related orphan receptor γ t (RORγt), encoded by Rorc, is the master transcriptional regulator defining the Th17 lineage (20), and IL-6–mediated STAT3 activation is important for RORγt-associated Th17 proliferation and survival (21).

IL-6 has been reported to promote T cell survival and limit apoptosis. IL-6 prevents activation-induced cell death by downregulating Fas and FasL in an IL-2–independent manner (22, 23). It further supports T cell survival through the maintenance of antiapoptotic factors (2427). The effect of IL-6 on T cell proliferation is less clear. Early IL-6 signaling drives expansion and cytokine production of primed or memory CD4+ T cells (28, 29). Mice that overexpress IL-6 have increased peripheral T cells, although this is not due to activation induced proliferation, as the cells remain quiescent and do not exhibit any change in activation/memory phenotype (27). Blockade of IL-6 signaling in T cells has been shown to result in a proliferative defect in naive T cells, particularly under lymphopenic conditions (30, 31). However, other studies have indicated that enhanced T cell survival in the presence of IL-6 is mediated by reduced apoptosis and not through increased proliferation (25). Thus, the direct effects of IL-6 on T cell proliferation, and any mechanism by which this may occur, remain unclear.

We previously reported that in contrast to wild type (WT) T cells, IL-6Rα–deficient T cells (IL-6RαTdel) do not induce colitis upon transfer into lymphodeficient Rag1−/− mice. This was associated with failure of the IL-6RαTdel T cells to effectively expand (32). Our findings indicated that IL-6 is broadly necessary for T cell expansion during colitis but did not identify the specific roles of lymphodeficiency and inflammation as drivers of this. We show in this study that IL-6Rα–deficient T cells are unable to effectively compete with WT T cells under lymphopenic and inflammatory conditions. This is due to inflammation induced IL-6 signaling into the cells and not the lymphopenic environment. We correlated this defect with reduced expression of Ki67 and RORγt. IL-6Rα–deficient T cells isolated from inflammatory conditions expressed minimal levels of Rorc mRNA. In contrast, WT T cells upregulated Rorc, although to levels substantially lower than that observed in Th17 T cells. Blockade of RORγt, either by genetic knockout or small molecule inhibitor, revealed a proliferative defect paralleling that seen in IL-6Rα–deficient T cells. Taken together our data indicate that whereas robust RORγt expression promotes and maintains Th17 differentiation, IL-6 signaling can also more broadly induce low level expression of RORγt that is correlated with T cell proliferation and expansion under inflammatory conditions.

B6.SJL-Ptprca Pepcb/BoyJ (CD45.1), B6.PL-Thy1a/CyJ (Thy1.1), B6.129S7-Rag1tm1Mom/J (Rag1−/−), and B6.SJL-Il6ratm1.1Drew/J (IL-6Rαfl/fl) mice were purchased from The Jackson Laboratory. IL-6Rαfl/fl mice possess loxP sites flanking exons 4–6 of the IL-6 receptor α (Il6ra) gene. IL-6Rαfl/fl mice were bred with B6.Tg(Cd4-Cre)1Cwi/BfluJ (CD4 cre) mice (H. Chi, St. Jude Children’s Research Hospital). The resulting IL-6Rαfl/fl CD4cre+ mice are referred to as IL-6RαTdel mice. All mice were maintained under specific pathogen free conditions, including negative for detectable Helicobacter spp. Experimental protocols were approved by the St. Jude Children’s Research Hospital Animal Care and Use Committee.

Naive CD4+CD25CD45RBhi T cells were sorted from spleens, and 1.0 × 106 cells were transferred i.v. into Rag1−/− mice. Body weight was monitored weekly. For IL-6Rα blockade, 1 mg anti–IL-6Rα mAb (clone 15A7; Bio X Cell) or control IgG was administered i.p. For RORγt inhibition, equal numbers (5 × 105) of indicated T cells were transferred into Rag1−/− mice. Three weeks later, mice were treated with the inhibitor GSK805 or a vehicle control daily for 1 wk. GSK805 was purchased from EMD Millipore with a purity ≥95% by HPLC. Mice received 10 mg/kg/day GSK805 dissolved in DMSO by oral gavage in corn oil or DMSO alone in corn oil as a vehicle control (33, 34). For cotransfers with regulatory T cells (Tregs), 1 × 106 naive CD4+CD25CD45RBhi T cells mixed with 0.2 × 106 CD4+CD25+CD45RBlo Tregs from WT (CD45.1) and IL-6RαTdel (CD45.2) mice were cotransferred together at a 1:1 ratio into Rag1−/− mice. Organs were harvested 3 wk later, and cells were distinguished by CD45.1/CD45.2 expression.

Naive CD4+CD25CD45RBhi T cells were sorted from spleens of IL-6RαTdel and WT mice. Cells were mixed at a ratio of 3:1, and 1 × 106 total cells per mouse were transferred i.v. into Rag1−/− mice. After 3 wk, 1 mg/kg LPS or PBS was given i.v. Organs were harvested and analyzed 1 wk after LPS treatment. For IL-6Rα blockade, 1 mg anti–IL-6Rα mAb (clone 15A7; Bio X Cell), which has been shown to neutralize IL-6 signaling in vivo (35), or control IgG was administered per mouse i.p., concurrent with LPS or PBS treatment. To test nonlymphopenic conditions, naive CD4+ T cells from WT (CD45.1+Thy1.2+) and IL-6RαTdel (CD45.2+Thy1.2+) mice were cotransferred into Thy1.1 mice at a 1:3 ratio (1 × 107 total cells/mouse). LPS (1 mg/kg) or PBS was administered i.v. 4 d after transfer. Organs were harvested 1 wk after LPS treatment.

Blood samples were obtained from retro-orbital puncture and immediately centrifuged at 4000 rpm for 15 min. Serum samples were stored at −20°C until ready to be used. Serum levels of IL-6 were measured either by Luminex (Bio-Rad Laboratories) or with a mouse IL-6 sandwich ELISA kit (eBioscience), according to manufacturer instructions.

Colon segments were vigorously shaken in medium with 1 mM EDTA (Sigma-Aldrich) for 20 min at 37°C, and suspended cells were collected and filtered through a cell strainer. Tissue was further minced and incubated at 37°C for 1 h in medium with 1 mM collagenase type IV (Sigma-Aldrich) and 40 U/ml DNase I (Roche) with agitation. Cells were filtered, washed, and isolated over a Percoll step gradient (32).

Cells were surface stained in FACS buffer (PBS with 2% FBS) as indicated, with the following fluorescently labeled mAbs specific for mouse: TCRβ-FITC (clone H57-597) CD45.2-FITC (clone 104), CD44-FITC (clone IM7), CD8–Pacific Blue (clone 53-6.7), and CD62L-PE-Cy7 (clone MEL-14) from BioLegend; CD4-allophycocyanin (clone RM4-5) from Tonbo Biosciences; CD45.1 allophycocyanin-Cy7 (clone A20) and CD69-PE (clone H1.2F3) from BD Biosciences; and Thy1.2-PE (clone 30-H12) and CD45RB-PE (clone C363.16A) from eBioscience. For intracellular staining, cells were restimulated with cell stimulation mixture containing Brefeldin A (eBioscience) for 4 h at 37°C, washed with FACS buffer, and surface stained at room temperature for 30 min. Cells were fixed and permeabilized with the Intracellular Fixation and Permeabilization Buffer Set (eBioscience) and stained with IL-17A–FITC (clone TC11-18H10.1; BioLegend), IFN-γ–allophycocyanin (clone XMG1.2; BioLegend), RORγt-PE (clone AFKJS-9; eBioscience), and Ki67-PerCP-Cy5.5 (clone B56; BD Biosciences). For Foxp3 staining, cells were surfaced stained as above, followed by fixation, permeabilization, and staining with Foxp3-PE (clone FJK-16s; eBioscience) using the Foxp3 Transcription Factor Buffer kit (eBioscience) according to manufacturer instructions. All samples were run on an LSRFortessa or LSR II flow cytometer (BD Biosciences), and data were analyzed using CellQuest (BD Biosciences) or FlowJo (Tree Star) software.

For BrdU, γH2AX, and cleaved-PARP staining, mice were injected i.p. with 100 μl of 10 mg/ml BrdU in PBS 24 h before analysis. Samples were prepared and stained using the Apoptosis, DNA Damage, and Cell Proliferation kit from BD Biosciences according to instructions. Briefly, samples were surface stained as described above for 30 min at room temperature. Cells were then fixed with BD Cytofix/Cytoperm solution for 30 min at room temperature, washed with BD Perm/Wash buffer, and treated with BD Cytofix/Cytoperm Plus Permeabilization buffer for 10 min on ice. Cells were washed with BD Perm/Wash buffer and refixed for 5 min at room temperature. Samples were then treated with 300 μg/ml DNAse for 1 h at 37°C to expose incorporated BrdU. Cells were then stained with anti-BrdU PerCP-Cy5.5 (clone 3D4), anti-H2AX (pS139)–Alexa Fluor 647 (clone N1-431), and anti–cleaved PARP(Asp214)–PE (clone F21-852). For annexin V and propidium iodide staining, cells were first surface stained as described above. Cells were washed once in PBS and once in Annexin binding buffer (BD Biosciences). Cells were stained with annexin V–allophycocyanin (BD Biosciences) in binding buffer for 15 min at room temperature. Cells were washed with and resuspended in binding buffer. Propidium Iodide Staining Solution (BD Biosciences) was added, and samples were assessed by flow cytometry within 2 h. Active caspase-3 levels were measured using the Active Caspase-3 Apoptosis Kit (BD Biosciences). Briefly, cells were surface stained as indicated above. Samples were washed twice in cold PBS and resuspended in BD Cytofix/Cytoperm solution and incubated for 20 min on ice. Cells were washed twice with BD Perm/Wash and stained with anti–active caspase-3–PE (clone C92-605) for 30 min at room temperature. Cells were washed with BD Perm/Wash, resuspended in FACS buffer, and analyzed by flow cytometry.

Cells were harvested, and mRNA expression of Rorc was analyzed on a single-cell level by flow cytometry in combination with CD4, TCRβ CD45.1, and RORγt protein staining using FlowRNA II Assay kit (PrimeFlow; Affymetrix/eBioscience) according to manufacturer instructions (36). Briefly, cells were washed with and resuspended in permeabilization buffer. Rorc mRNA was detected using an amplified signal fluorescence in situ hybridization technique as previously described (37). Briefly, target probe hybridization was performed using type 1 (Alexa Fluor 647) probes for Rorc mRNA (VB1-17129). Splenocytes were incubated for 2 h with the target probes at 40°C. All samples were then incubated with the preamplification reagent for 2 h and the amplification reagent for an additional 2 h at 40°C. After signal amplification, cells were incubated with labeled probes at 40°C for 1 h. Cells were washed and resuspended in staining buffer prior to acquisition.

Naive (CD4+CD25CD45RBhi) cells were isolated by cell sorting to >99% purity. Cells were cultured at 5 × 105 cells per well in 96-well plates precoated with 1 μg/ml anti-CD3 and 2 μg/ml anti-CD28 in complete RPMI 1640 media containing 20 ng/ml IL-6, 5 ng/ml TGF-β, 10 μg/ml neutralizing anti–IL-4, and 10 μg/ml neutralizing anti–IFN-γ. Negative control wells contained all reagents except IL-6. After 4 d, cells were collected for intracellular staining or Rorc mRNA detection (20, 38).

Statistical significance was calculated using Prism5 software (GraphPad). Specific tests used for each experiment are detailed in the figure legends.

To assess the impact of IL-6Rα deficiency on T cell expansion, naive CD4+CD25CD45RBhi T cells from WT or IL-6RαTdel mice were separately transferred into Rag1−/− hosts. Organs were analyzed 3 wk later, prior to the development of the overt inflammatory disease seen with this T cell transfer model. Spleens from IL-6RαTdel recipients were significantly smaller than those of recipients of WT T cells (Fig. 1A). Consistently, the number of CD4+ T cells in the spleen, mesenteric lymph node (MLN), and colon were dramatically reduced in recipients of IL-6RαTdel T cells relative to WT T cells (Fig. 1B). Thus, IL-6Rα is necessary for effective T cell expansion in these lymphopenic conditions.

FIGURE 1.

IL-6 promotes T cell expansion in a T cell transfer model. (A and B) Rag1−/− mice received 1 × 106 naive CD4+CD25CD45RBhi T cells from WT or IL-6RαTdel mice. Organs were harvested 3 wk after transfer and analyzed. Significance was determined by unpaired t test. (A) Spleens and plotted ratio of spleen weight/body weight. (B) Absolute numbers of CD4+TCRβ+ T cells in the spleen, MLN, and colon. (C) Equal numbers (0.5 × 106) of naive CD4+CD25CD45RBhi WT (CD45.1+) and IL-6RαTdel (CD45.2+) T cells were cotransferred i.v. into Rag1−/− mice. Organs were harvested 3 wk later. T cells were gated based on CD4 and TCRβ expression, and WT or IL-6RαTdel cells were distinguished based on CD45.1/CD45.2 expression. Representative dot plots and summary data from five mice per group are shown. Significance was determined by paired t test. (D) Serum was collected from Rag1−/− mice prior to T cell transfer or at the indicated time after cotransfer of WT and IL-6RαTdel T cells. Serum IL-6 concentrations were determined by ELISA. Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. All data are representative of two or more independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001.

FIGURE 1.

IL-6 promotes T cell expansion in a T cell transfer model. (A and B) Rag1−/− mice received 1 × 106 naive CD4+CD25CD45RBhi T cells from WT or IL-6RαTdel mice. Organs were harvested 3 wk after transfer and analyzed. Significance was determined by unpaired t test. (A) Spleens and plotted ratio of spleen weight/body weight. (B) Absolute numbers of CD4+TCRβ+ T cells in the spleen, MLN, and colon. (C) Equal numbers (0.5 × 106) of naive CD4+CD25CD45RBhi WT (CD45.1+) and IL-6RαTdel (CD45.2+) T cells were cotransferred i.v. into Rag1−/− mice. Organs were harvested 3 wk later. T cells were gated based on CD4 and TCRβ expression, and WT or IL-6RαTdel cells were distinguished based on CD45.1/CD45.2 expression. Representative dot plots and summary data from five mice per group are shown. Significance was determined by paired t test. (D) Serum was collected from Rag1−/− mice prior to T cell transfer or at the indicated time after cotransfer of WT and IL-6RαTdel T cells. Serum IL-6 concentrations were determined by ELISA. Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. All data are representative of two or more independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001.

Close modal

Transfer of naive WT T cells causes severe colitis and inflammatory bowel disease symptoms that are absent in mice that receive IL-6RαTdel cells (32). To separate the role of T cell–intrinsic IL-6 signaling from broader inflammation-associated changes, we performed cotransfers of naive WT and IL-6RαTdel T cells, allowing comparison of their expansion in an identical environment. Three weeks after transfer at a 1:1 ratio, WT cells were 3-fold more abundant than IL-6RαTdel cells in the spleen and MLN (Fig. 1C). A similar competitive disadvantage of IL-6RαTdel T cells was seen the colon (Fig. 1C). A significant increase in serum IL-6 was observed in recipient mice after T cell transfer, and this was maintained over the course of the experiment (Fig. 1D). These cotransfers indicate that the reduced proliferative capacity of IL-6Rα–deficient T cells results at least in part from cell-intrinsic effects of IL-6 signaling and not from differences in the inflammatory environments present after alternatively transferring WT or IL-6RαTdel T cells.

Naive T cells acquire an activated or memory-like phenotype during homeostatic proliferation (39). By 3 wk after cotransfer, both WT and IL-6RαTdel T cells developed a CD44hiCD62Llo phenotype with similar expression of these markers (data not shown). CD69 expression was likewise comparable in WT and IL-6RαTdel cells, indicating that the absence of IL-6 responsiveness did not inhibit T cell activation per se (Supplemental Fig. 1A).

As IL-6 is fundamental for Th17 differentiation, we also analyzed the proportions of Th17 cells in individually transferred WT and IL-6RαTdel cell populations. Not surprisingly, significantly fewer IL-6RαTdel than WT CD4+ cells expressed IL-17A (Supplemental Fig. 1B). However, only 3% of WT cells were IL-17A+, indicating that impaired Th17 cell differentiation in IL-6RαTdel cells could not account for the observed expansion defect. A modest although significantly diminished percentage of IFN-γ+ cells was also observed, implying that IL-6 response deficiency also impacted Th1 differentiation. No difference in Foxp3+ Treg representation was seen (Supplemental Fig. 1B), consistent with prior reports (30). This suggests that differential activation and differentiation is not responsible for the broadly diminished competitiveness of IL-6RαTdel T cells.

To determine if receptivity to IL-6 led to differential proliferation of CD4+ T cells, we assessed WT and IL-6RαTdel cells cotransferred in equal numbers into Rag1−/− recipients for the expression of proliferation markers at both an early and later timepoint (Fig. 2A). Three days after transfer, the ratio of WT to IL-6RαTdel cells remained ∼1:1 in the spleen (Fig. 2B). Very few cells were recovered from the MLN, and no cells were detected in the colon at this time point, preventing analysis at these sites. In vivo BrdU incorporation was significantly higher in WT cells than in IL-6RαTdel cells recovered from the same recipients (Fig. 2C). Expression of the proliferation maker Ki67 was also significantly increased in WT T cells (Fig. 2D). The basal levels of γH2AX in WT and IL-6RαTdel T cells were also assessed 3 d after cotransfer. Although γH2AX is a marker of DNA damage, increased basal levels are detected as cells progress from G1 to G2/M, making it a useful marker of cell-cycle progression (4042). Basal γH2AX levels were significantly higher in recovered WT than IL-6RαTdel cells (Fig. 2E). Overall, these results are consistent with reduced proliferation in IL-6Rα–deficient T cells at this early time point.

FIGURE 2.

IL-6 signaling promotes proliferation in T cells. Equal numbers (0.5 × 106) of naive CD4+CD25CD45RBhi WT (CD45.1) and IL-6RαTdel (CD45.2) T cells were cotransferred i.v. into Rag1−/− mice. Organs were harvested 3 d or 3 wk later as indicated. T cells were gated based on CD4 and TCRβ expression, and WT and IL-6RαTdel T cells were distinguished based on CD45.1/CD45.2 expression. (A) Experimental design schematic. (B) Percentage of CD4+TCRβ+ T cells in the spleen 3 d after transfer. (C) Percentage of BrdU+ T cells in the spleen 3 d after transfer. (D) Percentage of Ki67+ T cells in the spleen 3 d after transfer. (E) Level of γH2AX in T cells 3 d after transfer, shown as mean fluorescence intensity (MFI). (F) Percentage of BrdU+ T cells in the spleen, MLN, and colon 3 wk after transfer. (G) Percentage of Ki67+ T cells in the spleen, MLN, and colon 3 wk after transfer. (H) Level of γH2AX in T cells 3 wk after transfer, shown as MFI. Representative plots and summary data from four to five mice per group are shown. Significance was determined by paired t test. *p < 0.05, **p < 0.01.

FIGURE 2.

IL-6 signaling promotes proliferation in T cells. Equal numbers (0.5 × 106) of naive CD4+CD25CD45RBhi WT (CD45.1) and IL-6RαTdel (CD45.2) T cells were cotransferred i.v. into Rag1−/− mice. Organs were harvested 3 d or 3 wk later as indicated. T cells were gated based on CD4 and TCRβ expression, and WT and IL-6RαTdel T cells were distinguished based on CD45.1/CD45.2 expression. (A) Experimental design schematic. (B) Percentage of CD4+TCRβ+ T cells in the spleen 3 d after transfer. (C) Percentage of BrdU+ T cells in the spleen 3 d after transfer. (D) Percentage of Ki67+ T cells in the spleen 3 d after transfer. (E) Level of γH2AX in T cells 3 d after transfer, shown as mean fluorescence intensity (MFI). (F) Percentage of BrdU+ T cells in the spleen, MLN, and colon 3 wk after transfer. (G) Percentage of Ki67+ T cells in the spleen, MLN, and colon 3 wk after transfer. (H) Level of γH2AX in T cells 3 wk after transfer, shown as MFI. Representative plots and summary data from four to five mice per group are shown. Significance was determined by paired t test. *p < 0.05, **p < 0.01.

Close modal

The same parameters were also assessed 3 wk after T cell transfer, when cells had migrated to the MLN and colon, and WT cells were ∼3-fold more abundant than IL-6RαTdel cells. In vivo BrdU incorporation was significantly higher in WT cells than in IL-6RαTdel cells isolated from the MLN but not from the spleen or colon (Fig. 2F). More WT than IL-6RαTdel cells were Ki67+ 3 wk after transfer, and this was consistent across all organs (Fig. 2G). Finally, higher basal γH2AX levels were observed in WT cells in the spleen and MLN (Fig. 2H). Together, these data indicate that IL-6 responsiveness confers an increased proliferative capacity and that although IL-6RαTdel T cells become activated normally under lymphopenic and inflammatory conditions, they fail to proliferate at the same rate as WT T cells.

To determine if IL-6 deficiency led to increased cell death in CD4+ T cells, we also assessed WT and IL-6RαTdel cells cotransferred into Rag1−/− recipients for markers of cell death at early and late timepoints. Three days after transfer, there was no difference in levels of the apoptosis markers active caspase-3 or cleaved PARP between WT and IL-6RαTdel T cells in the spleens of recipient mice (Supplemental Fig. 2A, 2B). There were also no differences in the percentage of cells undergoing early and late stage apoptosis, as determined by annexin V/propidium iodide staining, between WT and IL-6RαTdel T cells (Supplemental Fig. 2C). Three weeks after cotransfer, there were still no differences observed in any of these parameters in the spleen, MLN, or colon (Supplemental Fig. 2D–F). These results indicated that decreased proliferation, and not increased apoptosis, of IL-6RαTdel T cells is responsible for their reduced expansion.

We next asked whether IL-6 signaling played a role in T cell expansion under nonlymphopenic and noninflammatory conditions by comparing IL-6RαTdel and IL-6Rαfl/fl CD4cre littermate control mice at 6–8 wk of age. The representation of CD4+ T cells among total T cells was not significantly different in the spleen or MLN of IL-6RαTdel mice relative to littermate controls (Fig. 3A). Naive and memory CD4+ T cell subpopulations were also equivalent in IL-6RαTdel mice and littermate controls (Fig. 3B). The ratio of spleen to body weight in IL-6RαTdel mice and littermate control mice was not significantly different, and the absolute numbers of splenocytes and total CD4+ T cells in the spleen and MLN of IL-6RαTdel mice were comparable to that of control mice (Fig. 3C). This indicates that the absence of IL-6 signaling did not adversely affect the formation of peripheral CD4+ T cell populations under noninflammatory conditions.

FIGURE 3.

IL-6 signaling is not required for T cell homeostasis under nonlymphopenic and noninflammatory conditions. (AC) Flow cytometric analysis of spleen and MLN from 8-wk-old IL-6RαTdel mice or IL-6Rαfl/fl CD4 cre littermates. T cells were gated based on CD4 and TCRβ expression. Representative dot plots and summary data from five mice per group are shown. Significance was determined by unpaired t test. (A) Percentage of CD4+ T cells. (B) Percentage of naive (CD44loCD45RBhi) and memory (CD44hiCD45RBlo) CD4+ T cells. (C) From left to right, ratio of spleen weight/body weight, absolute number of splenocytes, and absolute CD4+ T cell numbers in the spleen and MLN. (D) Equal numbers (0.5 × 106) of naive CD4+CD25CD45RBhi WT (CD45.1+) and IL-6RαTdel (CD45.2+) T cells were cotransferred i.v. into C57BL/6 mice congenic for Thy1.1. Spleens were harvested 2 wk after transfer. Percentage of WT or IL-6RαTdel T cells among total CD4+TCRβ+Thy1.2+ T cells in the spleen were identified by CD45.1 and CD45.2 expression. Experimental schematic, representative dot plots, and summary data from five mice are shown. Significance was determined by paired t test. All data are representative of at least two independent experiments.

FIGURE 3.

IL-6 signaling is not required for T cell homeostasis under nonlymphopenic and noninflammatory conditions. (AC) Flow cytometric analysis of spleen and MLN from 8-wk-old IL-6RαTdel mice or IL-6Rαfl/fl CD4 cre littermates. T cells were gated based on CD4 and TCRβ expression. Representative dot plots and summary data from five mice per group are shown. Significance was determined by unpaired t test. (A) Percentage of CD4+ T cells. (B) Percentage of naive (CD44loCD45RBhi) and memory (CD44hiCD45RBlo) CD4+ T cells. (C) From left to right, ratio of spleen weight/body weight, absolute number of splenocytes, and absolute CD4+ T cell numbers in the spleen and MLN. (D) Equal numbers (0.5 × 106) of naive CD4+CD25CD45RBhi WT (CD45.1+) and IL-6RαTdel (CD45.2+) T cells were cotransferred i.v. into C57BL/6 mice congenic for Thy1.1. Spleens were harvested 2 wk after transfer. Percentage of WT or IL-6RαTdel T cells among total CD4+TCRβ+Thy1.2+ T cells in the spleen were identified by CD45.1 and CD45.2 expression. Experimental schematic, representative dot plots, and summary data from five mice are shown. Significance was determined by paired t test. All data are representative of at least two independent experiments.

Close modal

To further investigate the role of IL-6 signaling in T cell persistence in lymphoid replete mice, we cotransferred equal numbers of naive CD45.1 WT and CD45.2 IL-6RαTdel T cells (Thy1.2+) into Thy1.1 congenic hosts. In contrast to results with lymphopenic Rag1−/− hosts, the 1:1 ratio of transferred WT/IL-6RαTdel T cells was maintained 2 wk after transfer (Fig. 3D). Therefore, IL-6 does not appear to have a detectable role in T cell expansion or persistence in lymphoid replete, disease-free animals.

Although serum concentrations of IL-6 are normally low or undetectable, they rapidly rise with inflammation and, in particular, the profound inflammation that occurs with conditions such as septic shock or hepatitis (2, 43, 44). Treatment of mice with LPS mimics sepsis and transiently induces IL-6, resulting in serum levels that peak after 3–6 h and return to basal level within 24 h (45). We observed a 3-fold greater expansion of WT T cells relative to IL-6RαTdel T cells 3 wk after cotransfer of equal numbers into Rag1−/− mice (Fig. 1C). We hypothesized that LPS treatment, through the induction of elevated levels of IL-6, would further promote expansion of WT T cells.

Naive T cells from WT or IL-6RαTdel mice were mixed at a ratio of 1:3 and transferred into Rag1−/− mice. Because of the accelerated expansion of the WT cells, an ∼1:1 ratio of the two populations was present 3 wk after transfer (Supplemental Fig. 3A). At this time, a nonlethal dose of LPS (1 mg/kg) or saline was administered (Fig. 4A). Serum concentrations of IL-6 increased from nearly undetectable to >3 ng/ml within 6 h (Supplemental Fig. 3B). One week after this treatment, the ratio of WT/IL-6RαTdel T cells further increased to 2:1 in mice that had received LPS but was virtually unchanged in mice receiving saline (Fig. 4B, Supplemental Fig. 3C).

FIGURE 4.

LPS-induced serum IL-6 further promotes T cell expansion. Naive CD4+CD25CD45RBhi T cells from WT (CD45.1) and IL-6RαTdel (CD45.2) mice were cotransferred into Rag1−/− mice at a 1:3 ratio (1 × 106 total cells per mouse). A single dose of LPS (1 mg/kg) or PBS was administered 3 wk posttransfer. Organs were collected 1 wk after LPS treatment. T cells were gated based on CD4 and TCRβ expression, and WT and IL-6RαTdel cells were distinguished by CD45.1/CD45.2 expression. (A) Schematic representation of experimental design. (B) Representative dot plots and calculated ratios of WT/IL-6RαTdel cells from spleen, MLN, and colon after PBS or LPS treatment. Significance was determined by paired t test. (C) Anti–IL-6Rα or control IgG was administered concurrent with LPS or PBS treatment. The ratios of WT/IL-6RαTdel cells in the spleen and MLN are shown, along with representative dot plots. Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. (D) Percentage of CD4+Ki67+ WT and IL-6RαTdel T cells in spleens of mice treated with LPS or PBS and anti–IL-6Rα or control IgG. Representative dot plots are also shown. Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. Data are representative of two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

FIGURE 4.

LPS-induced serum IL-6 further promotes T cell expansion. Naive CD4+CD25CD45RBhi T cells from WT (CD45.1) and IL-6RαTdel (CD45.2) mice were cotransferred into Rag1−/− mice at a 1:3 ratio (1 × 106 total cells per mouse). A single dose of LPS (1 mg/kg) or PBS was administered 3 wk posttransfer. Organs were collected 1 wk after LPS treatment. T cells were gated based on CD4 and TCRβ expression, and WT and IL-6RαTdel cells were distinguished by CD45.1/CD45.2 expression. (A) Schematic representation of experimental design. (B) Representative dot plots and calculated ratios of WT/IL-6RαTdel cells from spleen, MLN, and colon after PBS or LPS treatment. Significance was determined by paired t test. (C) Anti–IL-6Rα or control IgG was administered concurrent with LPS or PBS treatment. The ratios of WT/IL-6RαTdel cells in the spleen and MLN are shown, along with representative dot plots. Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. (D) Percentage of CD4+Ki67+ WT and IL-6RαTdel T cells in spleens of mice treated with LPS or PBS and anti–IL-6Rα or control IgG. Representative dot plots are also shown. Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. Data are representative of two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Close modal

To confirm that IL-6 was the primary factor promoting T cell expansion after LPS treatment, a blocking anti–IL-6Rα Ab (4648) or control IgG was administered concurrently with LPS or saline. As expected, the ratio of WT/IL-6RαTdel T cells increased significantly with LPS treatment in the presence of control IgG, but this effect was completely abrogated by neutralizing IL-6 Ab (Fig. 4C). Consistent with prior data indicating that this Ab is not depleting, there was no difference in the ratio of IL-6Rα–expressing WT to IL-6RαTdel cells in PBS-treated mice that received control IgG or IL-6Rα blocking Ab. LPS treatment also increased the percentage of proliferating WT Ki67+ cells, consistent with a role for IL-6 in supporting proliferation, and this effect was blocked by anti–IL-6Rα treatment (Fig. 4D). IL-6RαTdel T cells did modestly increase Ki67 in response to LPS treatment, although to a lesser degree than WT T cells, indicating a lesser role for other LPS-induced mediators. Taken together, these results indicate that intrinsic IL-6 signaling plays a central role in T cell expansion in response to LPS treatment and that elevated IL-6 levels are responsible.

Our results indicated that IL-6 signaling promotes T cell proliferation and expansion in an inflammatory and lymphopenic environment but not in a noninflammatory and lymphoid-sufficient one. We next asked if IL-6 signaling was sufficient to promote T cell expansion in the absence of lymphodepletion. Naive T cells from WT or IL-6RαTdel mice were mixed at a ratio of 1:3, transferred into lymphoid replete Thy1.1 hosts, and then treated with PBS or LPS as above. Similar to results in Fig. 3D, the PBS-treated group maintained the WT/IL-6RαTdel input ratio in the spleen (0.376 ± 0.016) and MLN (0.347 ± 0.020). LPS stimulation of these lymphoid replete mice, however, resulted in an increased ratio in the spleen (1.005 ± 0.075) and MLN (1.084 ± 0.073), indicating that IL-6–induced T cell expansion did not require prior lymphopenia (Fig. 5A).

FIGURE 5.

Inflammation-induced IL-6 and not lymphopenia promotes T cell expansion. (A) Naive CD4+ T cells from WT (CD45.1+Thy1.2+) and IL-6RαTdel (CD45.2+Thy1.2+) mice were cotransferred into Thy1.1 mice at a 1:3 ratio. LPS or PBS was administered 4 d after transfer. Organs were harvested 1 wk later, and the ratio of WT to IL-6RαTdel cells was determined. Schematic of experimental design, representative dot plots, and summary data from 10 mice pooled from two independent experiments are shown. Significance was determined by paired t test. (B) A total of 1 × 106 naive CD4+CD25CD45RBhi T cells and 0.2 × 106 CD4+CD25+CD45RBlo Tregs were mixed. This mixture from WT (CD45.1+) and IL-6RαTdel (CD45.2+) mice was cotransferred 1:1 into Rag1−/− mice. Organs were harvested 3 wk later, and the percentage of WT and IL-6RαTdel CD4+ cells was determined. Schematic of experimental design, representative dot plots, and summary data from 10 mice pooled from two independent experiments are shown. Significance was determined by paired t test. ****p < 0.0001.

FIGURE 5.

Inflammation-induced IL-6 and not lymphopenia promotes T cell expansion. (A) Naive CD4+ T cells from WT (CD45.1+Thy1.2+) and IL-6RαTdel (CD45.2+Thy1.2+) mice were cotransferred into Thy1.1 mice at a 1:3 ratio. LPS or PBS was administered 4 d after transfer. Organs were harvested 1 wk later, and the ratio of WT to IL-6RαTdel cells was determined. Schematic of experimental design, representative dot plots, and summary data from 10 mice pooled from two independent experiments are shown. Significance was determined by paired t test. (B) A total of 1 × 106 naive CD4+CD25CD45RBhi T cells and 0.2 × 106 CD4+CD25+CD45RBlo Tregs were mixed. This mixture from WT (CD45.1+) and IL-6RαTdel (CD45.2+) mice was cotransferred 1:1 into Rag1−/− mice. Organs were harvested 3 wk later, and the percentage of WT and IL-6RαTdel CD4+ cells was determined. Schematic of experimental design, representative dot plots, and summary data from 10 mice pooled from two independent experiments are shown. Significance was determined by paired t test. ****p < 0.0001.

Close modal

Inflammation in the Rag1−/− T cell transfer colitis model can be abrogated by cotransfer of Tregs (49). To further isolate the roles of inflammation and lymphopenia in the proliferative deficiency of IL-6RαTdel T cells, naive cells and Tregs were mixed at a 5:1 ratio. Mixtures from WT and IL-6RαTdel mice were then cotransferred at a 1:1 ratio into Rag1−/− mice. Three weeks later, the presence of Tregs and resulting curtailed inflammation led to preservation of the 1:1 ratio of WT/IL-6RαTdel cells in the spleen and MLN of recipient mice (Fig. 5B). Taken together, these results indicate that T cell–intrinsic IL-6 signaling promotes T cell proliferation and expansion in the context of inflammation and IL-6 production. Lymphopenia itself does not foster this enhanced proliferation in the absence of inflammation, such as that occurring after naive T cell transfer.

Although IL-6 enhances Th17 proliferation, reduced proliferation of IL-6RαTdel T cells was observed in cotransfers despite the absence of a substantial Th17 presence (Supplemental Fig. 1B). Our results suggested that the effect of IL-6 on T cell proliferation and expansion was independent of its role in promoting Th17 differentiation. However, our findings did not exclude a role for IL-6–induced RORγt, the master transcriptional regulator of Th17 differentiation. We therefore asked whether RORγt expression correlated with expression of the Ki67 proliferation marker in our cotransfer model (Fig. 6A). Three weeks after cotransfer at a 1:1 ratio, fewer IL-6RαTdel T cells were RORγt+ than WT T cells, as would be anticipated owing to the absence of IL-6 signaling (Fig. 6B, 6C). For either transferred population, the percentage of Ki67+ T cells was significantly higher within the RORγt+ than RORγt population in all organs, indicating an association between RORγt expression and proliferation (Fig. 6B, 6C). This indicates that low-level RORγt expression in T cells is associated with T cell proliferation and implies that the relative failure of RORγt upregulation in IL-6RαTdel versus WT cells may account for the reduced IL-6RαTdel T cell proliferation and expansion.

FIGURE 6.

Low-level expression of RORγt is associated with T cell proliferation. Naive CD4+CD25CD45RBhi T cells from WT (CD45.1+) and IL-6RαTdel (CD45.2+) mice were transferred into Rag1−/− mice at a 1:1 ratio. Spleens were collected 3 wk after transfer, and CD45.1/CD45.2 expression was used to differentiate WT and IL-6RαTdel cells. (A) Schematic of experimental design. (B) Gating strategy and representative dot plots and (C) summary data showing RORγt and Ki67 expression in WT and IL-6RαTdel T cells from spleen, MLN, and colon. Data from 10 mice pooled from two independent experiments are shown. Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. (D) Rorc mRNA probe was used to flow cytometrically detect Rorc mRNA in WT and IL-6RαTdel T cells isolated from cotransfers into three Rag1−/− mice. In vitro differentiated WT Th17 cells and RORγt−/− T cells were used as positive and negative controls, respectively. The mean fluorescence intensity (MFI) of each group is also plotted. Data are representative of two independent experiments with three mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

FIGURE 6.

Low-level expression of RORγt is associated with T cell proliferation. Naive CD4+CD25CD45RBhi T cells from WT (CD45.1+) and IL-6RαTdel (CD45.2+) mice were transferred into Rag1−/− mice at a 1:1 ratio. Spleens were collected 3 wk after transfer, and CD45.1/CD45.2 expression was used to differentiate WT and IL-6RαTdel cells. (A) Schematic of experimental design. (B) Gating strategy and representative dot plots and (C) summary data showing RORγt and Ki67 expression in WT and IL-6RαTdel T cells from spleen, MLN, and colon. Data from 10 mice pooled from two independent experiments are shown. Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. (D) Rorc mRNA probe was used to flow cytometrically detect Rorc mRNA in WT and IL-6RαTdel T cells isolated from cotransfers into three Rag1−/− mice. In vitro differentiated WT Th17 cells and RORγt−/− T cells were used as positive and negative controls, respectively. The mean fluorescence intensity (MFI) of each group is also plotted. Data are representative of two independent experiments with three mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Close modal

On a more refined level, we also observed that the percentage of Ki67+ cells was higher in WT relative to IL-6RαTdel cells among either the RORγt or RORγt+ populations (Fig. 6C). This suggests either that RORγt cannot fully account for the proliferative discrepancies observed between WT and IL-6RαTdel cells or that differences in the level of RORγt expression between the cell populations that are not adequately resolved through our flow cytometric assay impact T cell expansion.

Because intracellular staining of RORγt was weak in the transferred T cells, we also examined differences in Rorc mRNA expression. This was measured using a flow cytometry–based assay that significantly amplifies RNA signal (36). Cotransfers of WT and IL-6RαTdel T cells were performed as described above, and transferred cells were isolated 3 wk later and stained with a probe specific for Rorc mRNA. In vitro differentiated WT Th17 cells and T cells from RORγt−/− mice were used as positive and negative controls, respectively. The Th17 cells expressed high Rorc mRNA levels, an order of magnitude greater than that observed in the transferred WT T cells, consistent with the role of RORγt as the primary mediator of Th17 differentiation. WT and IL-6RαTdel T cells from cotransfers expressed intermediate and low levels of Rorc RNA, respectively, relative to the RORγt-deficient cells (Fig. 6D). Taken together, these data suggest that IL-6 promotes a range of Rorc expression, with high expression associated with the Th17 lineage, low expression correlated with the enhanced cell proliferation among WT T cells, and further reduced expression in the relatively hypoproliferative IL-6RαTdel T cells.

To further address the role of RORγt in T cell expansion, we performed 1:1 cotransfers of WT and RORγt−/− T cells into Rag1−/− mice (Fig. 7A). Similar to cotransfers with IL-6RαTdel cells, WT T cells significantly outnumbered RORγt−/− T cells 2:1 by 3 wk after transfer (Fig. 7B). The percentage of Ki67+ RORγt−/− T cells was also reduced relative to WT T cells in all organs, indicating that RORγt status is associated with Ki67 expression and proliferation (Fig. 7C, Supplemental Fig. 4A). In contrast, there was no significant difference in the percent of activated caspase-3+ WT and RORγt−/− T cells, suggesting that similar to IL-6 receptivity, RORγt expression does not influence apoptosis (Fig. 7D, Supplemental Fig. 4B). Taken together, these results indicate that IL-6 induces low levels of RORγt in transferred WT T cells and that this IL-6–induced RORγt is associated with T cell proliferation in this setting. These findings do not exclude added effects of other IL-6 induced signaling pathways.

FIGURE 7.

Blockade of RORγt inhibits T cell expansion. (AD) Naive CD4+CD25CD45RBhi T cells from WT (CD45.1+) or RORγt−/− (CD45.2+) mice were transferred 1:1 into Rag1−/− mice. Organs were harvested 3 wk posttransfer. CD4+ T cells were gated based on CD4 and TCRβ, and WT and RORγt−/− T cells were distinguished based on CD45.1/CD45.2 expression. (A) Schematic of experimental design. (B) Percentage of WT and RORγt−/− T cells among total CD4+ transferred cells, (C) percentage of Ki67+, and (D) percentage active caspase-3+ WT or RORγt−/− T cells in the spleen, MLN, and colon. Significance was determined by paired t test. (EG) Naive CD4+CD25CD45RBhi T cells from WT or IL-6RαTdel mice were transferred into Rag−/− mice at a 1:1 ratio. After 3 wk, mice were treated daily with an ROR inhibitor (GSK805). Organs were harvested 1 wk later. (E) Schematic of experimental design. (F) Representative dot plots and summary data showing the ratio of WT to IL-6RαTdel cells. Significance was determined by paired t test. (G) Percentage Ki67+ WT or IL-6RαTdel cells after treatment with RORγt inhibitor or DMSO (vehicle control). Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. All data are representative of two independent experiments with five mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

FIGURE 7.

Blockade of RORγt inhibits T cell expansion. (AD) Naive CD4+CD25CD45RBhi T cells from WT (CD45.1+) or RORγt−/− (CD45.2+) mice were transferred 1:1 into Rag1−/− mice. Organs were harvested 3 wk posttransfer. CD4+ T cells were gated based on CD4 and TCRβ, and WT and RORγt−/− T cells were distinguished based on CD45.1/CD45.2 expression. (A) Schematic of experimental design. (B) Percentage of WT and RORγt−/− T cells among total CD4+ transferred cells, (C) percentage of Ki67+, and (D) percentage active caspase-3+ WT or RORγt−/− T cells in the spleen, MLN, and colon. Significance was determined by paired t test. (EG) Naive CD4+CD25CD45RBhi T cells from WT or IL-6RαTdel mice were transferred into Rag−/− mice at a 1:1 ratio. After 3 wk, mice were treated daily with an ROR inhibitor (GSK805). Organs were harvested 1 wk later. (E) Schematic of experimental design. (F) Representative dot plots and summary data showing the ratio of WT to IL-6RαTdel cells. Significance was determined by paired t test. (G) Percentage Ki67+ WT or IL-6RαTdel cells after treatment with RORγt inhibitor or DMSO (vehicle control). Significance was determined by one-way ANOVA with Tukey posttest for multiple comparisons. All data are representative of two independent experiments with five mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Close modal

As an additional approach to confirm the role of RORγt in T cell expansion, we performed cotransfer experiments using an RORγt inhibitor, GSK805. Naive WT and IL-6RαTdel T cells were cotransferred at a 1:1 ratio into Rag1−/− mice. Three weeks later, mice were treated with inhibitor or a vehicle control daily for 1 wk (Fig. 7E). As expected, mice that did not receive inhibitor had 2- to 3-fold more WT T cells than IL-6RαTdel cells. After 1 wk of inhibitor treatment, this effect was partially abrogated, resulting in ratios of ∼1.5:1 of WT/IL-6RαTdel cells (Fig. 7F). Importantly, RORγt inhibitor treatment reduced the percentage of Ki67+ WT cells such that there was no difference between WT and IL-6RαTdel cells (Fig. 7G, Supplemental Fig. 4C). Therefore, inhibition of RORγt protein reduces the proliferative capacity of WT T cells. Cumulatively, these results identify low-level expression of IL-6–induced RORγt as a novel factor that is associated with T cell proliferation and expansion.

IL-6 can enhance T cell survival and proliferation (25), although the impact of these effects and the mechanisms by which they occur are unclear. In this study, we show that IL-6–induced RORγt is associated with T cell proliferation and expansion, specifically under inflammatory conditions. T cell–intrinsic IL-6 signaling induces low-level expression of RORγt which is associated with T cell proliferation, and this appears to be independent from the role of RORγt in Th17 programing. Blockade of RORγt, either by inhibition or genetic deletion, reduces proliferation and expansion toward levels observed in T cells unable to respond to IL-6, suggesting that IL-6–induced upregulation of RORγt is largely responsible for IL-6’s effects. Genetic deletion of RORγt was limited to T cells in our transfer model, ensuring that RORγt expression by innate lymphoid cells and their potential effects on T cell expansion were unaltered. Further, the use of cotransfers of WT and deficient T cells permitted a direct comparison of the cell intrinsic effects of RORγt on T cells in identical environments.

Our prior observations demonstrating an obligate role for IL-6 responsiveness in T cell expansion and colitis induction in lymphoid deficient Rag1−/− mice led us to further explore the role of IL-6 in this study. IL-6–induced RORγt promotes Th17 cell development and is necessary for colitis. Inflammation induced by the transfer of naive T cells into lymphopenic mice is dependent on pathogenic Th17 cells and is RORγt dependent (50). The failure of transferred IL-6RαTdel cells to induce colitis may have resulted from diminished Th17 development or defective T cell expansion (32). IL-17–producing cells constitute only 15–20% of T cells in the colon lamina propria and MLN in T cell transfer colitis models at 8 wk after transfer when disease pathology is maximal (51). However, we observe in our study expansion defects in IL-6RαTdel cells even 3 wk after transfer when no overt disease symptoms are present, and only 3% of T cells in the colon are IL-17+. More significantly, IL-6RαTdel T cells fail to effectively compete with cotransferred WT T cells despite effective Th17 formation by the WT T cells and development of colitis at late time points in this cotransfer model (data not shown). Therefore, IL-6 responsiveness is necessary for effective T cell expansion after transfer into lymphopenic animals, and the competitive disadvantage of IL-6–unresponsive T cells persists even when Th17-induced inflammation is restored by the cotransfer of WT T cells.

IL-6–induced RORγt also inhibits the conversion of T cells to Foxp3+ regulatory cells and increases Th17 differentiation (3, 52, 53). It is possible that differential expression of RORγt in WT and IL-6RαTdel cells may influence their ability to convert to Foxp3+ Tregs and thus their ability to expand, as Tregs suppress inflammation and proliferation in T cell transfer colitis. However, this appears unlikely as there are no differences in the percentage of Foxp3+ cells between the WT or IL-6RαTdel populations. In addition, the use of a cotransfer system in our study ensures that expansion of both WT and IL-6RαTdel cells are equally suppressed by any Tregs in the environment, regardless of their ability to be converted.

Using low-dose LPS to transiently boost serum IL-6 levels, we demonstrate that heightening IL-6 levels above baseline intensifies T cell expansion. The effect of LPS is predominantly dependent on IL-6 signaling and is observed both in lymphodeficient and lymphoreplete transfer models, demonstrating that IL-6’s actions are not exclusive to a lymphocyte-deficient setting. We did observe a slight increase in the number of IL-6RαTdel T cells upon LPS treatment, indicating a possible influence of other cytokine pathways. LPS is a strong inducer of the TLR4–Myd88–NF-κB and TRIF pathways (54, 55), which lead to production of an abundance of inflammatory cytokines (56) that may have IL-6–independent effects on T cell expansion. Regardless, the significant competitive disadvantage of IL-6RαTdel cells in the presence of LPS stimulation supports a primary role for IL-6 in inflammation-induced T cell expansion.

IL-6 initiates signaling via two mechanisms. Classical cis-mediated signaling takes place when cells express both IL-6Rα and gp130, and binding of soluble IL-6 triggers signaling. IL-6Rα also exists as a soluble receptor that can bind to IL-6 in solution and initiate trans-signaling on cells that express only gp130 (57). Thus, it is possible that IL-6 in the serum may bind to soluble IL-6Rα produced by other cell types and initiate trans-signaling in IL-6RαTdel T cells, which retain expression of gp130. Classical IL-6 signaling has been implicated in T cell transfer colitis models (58), whereas trans-signaling is seen in Crohn's disease and rheumatoid arthritis (24, 59). Effects of IL-6 trans-signaling would be controlled for by cotransfers of WT and IL-6RαTdel, and we obtained similar results from transfers of individual populations and cotransfer of both populations. Our results were also similar using an anti–IL-6Rα Ab, which would eliminate both cis- and trans-mediated IL-6 signaling. Thus, our data imply that the impact of trans-signaling is relatively minor here and that IL-6Rα acts largely cell intrinsically to promote T cell expansion in inflammatory environments.

Considering the minimal quantities of IL-6 present under normal physiological conditions and its rapid rise with inflammation, the low-level expression of RORγt induced via IL-6 may prime T cells to begin proliferating in circumstances where rapid expansion is necessary for optimal immune function. IL-6 alone may initiate low-level RORγt expression and T cell expansion, whereas IL-6 in concert with other cytokines, including TGF-β, IL-1β, or IL-23, induces higher levels of RORγt that promote Th17 development (60, 61). One possibility is that STAT1 or STAT3 activation induced by IL-6 alone may promote low level RORγt expression, whereas additional signaling pathways stimulated by other cytokines are needed to more fully drive RORγt expression and Th17 conversion. Taken together, our results suggest a proproliferative role for IL-6–induced RORγt that promotes T cell expansion under inflammatory conditions. A Food and Drug Administration–approved inhibitor of the IL-6 pathway has already proven efficacious in cytokine release syndrome, rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease and is being evaluated for other conditions. An improved understanding of IL-6’s role in modifying inflammatory responses will be essential for the proper use of this and similar agents.

We thank Richard Cross and Grieg Lennon for assistance with flow cytometric sorting and Richard Ashmun for assistance with the RNA flow assay.

This work was supported by National Institutes of Health Grant P30CA021765 and by St. Jude Children's Research Hospital/American Lebanese Syrian Associated Charities.

The online version of this article contains supplemental material.

Abbreviations used in this article:

MLN

mesenteric lymph node

RORγt

retinoic acid–related orphan receptor γ t

Treg

regulatory T cell

WT

wild type.

1
Dienz
,
O.
,
M.
Rincon
.
2009
.
The effects of IL-6 on CD4 T cell responses.
Clin. Immunol.
130
:
27
33
.
2
Hunter
,
C. A.
,
S. A.
Jones
.
2015
.
IL-6 as a keystone cytokine in health and disease.
Nat. Immunol.
16
:
448
457
.
3
Bettelli
,
E.
,
Y.
Carrier
,
W.
Gao
,
T.
Korn
,
T. B.
Strom
,
M.
Oukka
,
H. L.
Weiner
,
V. K.
Kuchroo
.
2006
.
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
Nature
441
:
235
238
.
4
Mihara
,
M.
,
M.
Hashizume
,
H.
Yoshida
,
M.
Suzuki
,
M.
Shiina
.
2012
.
IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Clin. Sci. (Lond.)
122
:
143
159
.
5
Pålsson-McDermott
,
E. M.
,
L. A.
O’Neill
.
2004
.
Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.
Immunology
113
:
153
162
.
6
Kamimura
,
D.
,
K.
Ishihara
,
T.
Hirano
.
2003
.
IL-6 signal transduction and its physiological roles: the signal orchestration model.
Rev. Physiol. Biochem. Pharmacol.
149
:
1
38
.
7
Tanaka
,
T.
,
M.
Narazaki
,
T.
Kishimoto
.
2012
.
Therapeutic targeting of the interleukin-6 receptor.
Annu. Rev. Pharmacol. Toxicol.
52
:
199
219
.
8
Kimura
,
A.
,
T.
Kishimoto
.
2010
.
IL-6: regulator of Treg/Th17 balance.
Eur. J. Immunol.
40
:
1830
1835
.
9
Atreya
,
R.
,
M. F.
Neurath
.
2005
.
Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer.
Clin. Rev. Allergy Immunol.
28
:
187
196
.
10
Boulanger
,
M. J.
,
D. C.
Chow
,
E. E.
Brevnova
,
K. C.
Garcia
.
2003
.
Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.
Science
300
:
2101
2104
.
11
Chalaris
,
A.
,
C.
Garbers
,
B.
Rabe
,
S.
Rose-John
,
J.
Scheller
.
2011
.
The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
Eur. J. Cell Biol.
90
:
484
494
.
12
Zhong
,
Z.
,
Z.
Wen
,
J. E.
Darnell
Jr
.
1994
.
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.
Science
264
:
95
98
.
13
Garbers
,
C.
,
S.
Aparicio-Siegmund
,
S.
Rose-John
.
2015
.
The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.
Curr. Opin. Immunol.
34
:
75
82
.
14
Kopf
,
M.
,
H.
Baumann
,
G.
Freer
,
M.
Freudenberg
,
M.
Lamers
,
T.
Kishimoto
,
R.
Zinkernagel
,
H.
Bluethmann
,
G.
Köhler
.
1994
.
Impaired immune and acute-phase responses in interleukin-6-deficient mice.
Nature
368
:
339
342
.
15
Yoshida
,
K.
,
T.
Taga
,
M.
Saito
,
S.
Suematsu
,
A.
Kumanogoh
,
T.
Tanaka
,
H.
Fujiwara
,
M.
Hirata
,
T.
Yamagami
,
T.
Nakahata
, et al
.
1996
.
Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders.
Proc. Natl. Acad. Sci. USA
93
:
407
411
.
16
Jones
,
L. L.
,
R.
Alli
,
B.
Li
,
T. L.
Geiger
.
2016
.
Differential T cell cytokine receptivity and not signal quality distinguishes IL-6 and IL-10 signaling during Th17 differentiation.
J. Immunol.
196
:
2973
2985
.
17
Harrington
,
L. E.
,
R. D.
Hatton
,
P. R.
Mangan
,
H.
Turner
,
T. L.
Murphy
,
K. M.
Murphy
,
C. T.
Weaver
.
2005
.
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
Nat. Immunol.
6
:
1123
1132
.
18
Park
,
H.
,
Z.
Li
,
X. O.
Yang
,
S. H.
Chang
,
R.
Nurieva
,
Y. H.
Wang
,
Y.
Wang
,
L.
Hood
,
Z.
Zhu
,
Q.
Tian
,
C.
Dong
.
2005
.
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.
Nat. Immunol.
6
:
1133
1141
.
19
Veldhoen
,
M.
,
R. J.
Hocking
,
C. J.
Atkins
,
R. M.
Locksley
,
B.
Stockinger
.
2006
.
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.
Immunity
24
:
179
189
.
20
Ivanov
,
I. I.
,
B. S.
McKenzie
,
L.
Zhou
,
C. E.
Tadokoro
,
A.
Lepelley
,
J. J.
Lafaille
,
D. J.
Cua
,
D. R.
Littman
.
2006
.
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.
Cell
126
:
1121
1133
.
21
Durant
,
L.
,
W. T.
Watford
,
H. L.
Ramos
,
A.
Laurence
,
G.
Vahedi
,
L.
Wei
,
H.
Takahashi
,
H. W.
Sun
,
Y.
Kanno
,
F.
Powrie
,
J. J.
O’Shea
.
2010
.
Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis.
Immunity
32
:
605
615
.
22
Adkins
,
B.
,
K.
Chun
,
K.
Hamilton
,
M.
Nassiri
.
1996
.
Naive murine neonatal T cells undergo apoptosis in response to primary stimulation.
J. Immunol.
157
:
1343
1349
.
23
Ayroldi
,
E.
,
O.
Zollo
,
L.
Cannarile
,
F.
D’ Adamio
,
U.
Grohmann
,
D. V.
Delfino
,
C.
Riccardi
.
1998
.
Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/fasL expression and cell death.
Blood
92
:
4212
4219
.
24
Atreya
,
R.
,
J.
Mudter
,
S.
Finotto
,
J.
Müllberg
,
T.
Jostock
,
S.
Wirtz
,
M.
Schütz
,
B.
Bartsch
,
M.
Holtmann
,
C.
Becker
, et al
.
2000
.
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. [Published erratum appears in 2010 Nat. Med. 16: 1341.]
Nat. Med.
6
:
583
588
.
25
Rochman
,
I.
,
W. E.
Paul
,
S. Z.
Ben-Sasson
.
2005
.
IL-6 increases primed cell expansion and survival.
J. Immunol.
174
:
4761
4767
.
26
Teague
,
T. K.
,
P.
Marrack
,
J. W.
Kappler
,
A. T.
Vella
.
1997
.
IL-6 rescues resting mouse T cells from apoptosis.
J. Immunol.
158
:
5791
5796
.
27
Hong
,
C.
,
A. S.
Nam
,
H. R.
Keller
,
D. L.
Ligons
,
J. Y.
Park
,
H. W.
Yoon
,
J. J.
Park
,
M. A.
Luckey
,
J. H.
Park
.
2013
.
Interleukin-6 expands homeostatic space for peripheral T cells.
Cytokine
64
:
532
540
.
28
Strutt
,
T. M.
,
K. K.
McKinstry
,
Y.
Kuang
,
C. M.
Finn
,
J. H.
Hwang
,
K.
Dhume
,
S.
Sell
,
S. L.
Swain
.
2016
.
Direct IL-6 signals maximize protective secondary CD4 T cell responses against influenza.
J. Immunol.
197
:
3260
3270
.
29
Longhi
,
M. P.
,
K.
Wright
,
S. N.
Lauder
,
M. A.
Nowell
,
G. W.
Jones
,
A. J.
Godkin
,
S. A.
Jones
,
A. M.
Gallimore
.
2008
.
Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells.
PLoS Pathog.
4
:
e1000006
.
30
Nish
,
S. A.
,
D.
Schenten
,
F. T.
Wunderlich
,
S. D.
Pope
,
Y.
Gao
,
N.
Hoshi
,
S.
Yu
,
X.
Yan
,
H. K.
Lee
,
L.
Pasman
, et al
.
2014
.
T cell-intrinsic role of IL-6 signaling in primary and memory responses.
eLife
3
:
e01949
.
31
Tajima
,
M.
,
D.
Wakita
,
D.
Noguchi
,
K.
Chamoto
,
Z.
Yue
,
K.
Fugo
,
H.
Ishigame
,
Y.
Iwakura
,
H.
Kitamura
,
T.
Nishimura
.
2008
.
IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells.
J. Exp. Med.
205
:
1019
1027
.
32
Li
,
B.
,
P.
Gurung
,
R. K.
Malireddi
,
P.
Vogel
,
T. D.
Kanneganti
,
T. L.
Geiger
.
2015
.
IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis.
Nat. Commun.
6
:
6131
.
33
Withers
,
D. R.
,
M. R.
Hepworth
,
X.
Wang
,
E. C.
Mackley
,
E. E.
Halford
,
E. E.
Dutton
,
C. L.
Marriott
,
V.
Brucklacher-Waldert
,
M.
Veldhoen
,
J.
Kelsen
, et al
.
2016
.
Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells.
Nat. Med.
22
:
319
323
.
34
Xiao
,
S.
,
N.
Yosef
,
J.
Yang
,
Y.
Wang
,
L.
Zhou
,
C.
Zhu
,
C.
Wu
,
E.
Baloglu
,
D.
Schmidt
,
R.
Ramesh
, et al
.
2014
.
Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms.
Immunity
40
:
477
489
.
35
Vink
,
A.
,
P.
Coulie
,
G.
Warnier
,
J. C.
Renauld
,
M.
Stevens
,
D.
Donckers
,
J.
Van Snick
.
1990
.
Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.
J. Exp. Med.
172
:
997
1000
.
36
Porichis
,
F.
,
M. G.
Hart
,
M.
Griesbeck
,
H. L.
Everett
,
M.
Hassan
,
A. E.
Baxter
,
M.
Lindqvist
,
S. M.
Miller
,
D. Z.
Soghoian
,
D. G.
Kavanagh
, et al
.
2014
.
High-throughput detection of miRNAs and gene-specific mRNA at the single-cell level by flow cytometry.
Nat. Commun.
5
:
5641
.
37
Henning
,
A. L.
,
B. K.
McFarlin
.
2017
.
Consumption of a high-fat, high-calorie meal is associated with an increase in intracellular co-localization of PPAR-γ mRNA and protein in monocytes.
Methods.
112
:
182
187
.
38
Pappu
,
B. P.
,
C.
Dong
.
2007
.
Measurement of interleukin-17.
Curr. Protoc. Immunol.
Chapter 6
:
Unit 6.25
.
39
Jameson
,
S. C.
2002
.
Maintaining the norm: T-cell homeostasis.
Nat. Rev. Immunol.
2
:
547
556
.
40
An
,
J.
,
Y. C.
Huang
,
Q. Z.
Xu
,
L. J.
Zhou
,
Z. F.
Shang
,
B.
Huang
,
Y.
Wang
,
X. D.
Liu
,
D. C.
Wu
,
P. K.
Zhou
.
2010
.
DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression.
BMC Mol. Biol.
11
:
18
.
41
Tu
,
W. Z.
,
B.
Li
,
B.
Huang
,
Y.
Wang
,
X. D.
Liu
,
H.
Guan
,
S. M.
Zhang
,
Y.
Tang
,
W. Q.
Rang
,
P. K.
Zhou
.
2013
.
γH2AX foci formation in the absence of DNA damage: mitotic H2AX phosphorylation is mediated by the DNA-PKcs/CHK2 pathway.
FEBS Lett.
587
:
3437
3443
.
42
MacPhail
,
S. H.
,
J. P.
Banáth
,
Y.
Yu
,
E.
Chu
,
P. L.
Olive
.
2003
.
Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells.
Radiat. Res.
159
:
759
767
.
43
Neurath
,
M. F.
,
S.
Finotto
.
2011
.
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
Cytokine Growth Factor Rev.
22
:
83
89
.
44
Trautwein
,
C.
,
T.
Rakemann
,
N. P.
Malek
,
J.
Plümpe
,
G.
Tiegs
,
M. P.
Manns
.
1998
.
Concanavalin A-induced liver injury triggers hepatocyte proliferation.
J. Clin. Invest.
101
:
1960
1969
.
45
Zhang
,
X.
,
Y.
Kimura
,
C.
Fang
,
L.
Zhou
,
G.
Sfyroera
,
J. D.
Lambris
,
R. A.
Wetsel
,
T.
Miwa
,
W. C.
Song
.
2007
.
Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo.
Blood
110
:
228
236
.
46
Koizumi
,
N.
,
T.
Yamaguchi
,
K.
Kawabata
,
F.
Sakurai
,
T.
Sasaki
,
Y.
Watanabe
,
T.
Hayakawa
,
H.
Mizuguchi
.
2007
.
Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production.
J. Immunol.
178
:
1767
1773
.
47
König
,
C.
,
E.
Morch
,
A.
Eitner
,
C.
Möller
,
B.
Turnquist
,
H. G.
Schaible
,
A.
Ebersberger
.
2016
.
Involvement of spinal IL-6 trans-signaling in the induction of hyperexcitability of deep dorsal horn neurons by spinal tumor necrosis factor-alpha.
J. Neurosci.
36
:
9782
9791
.
48
Barber
,
D. L.
,
B. B.
Andrade
,
C.
McBerry
,
I.
Sereti
,
A.
Sher
.
2014
.
Role of IL-6 in Mycobacterium avium--associated immune reconstitution inflammatory syndrome.
J. Immunol.
192
:
676
682
.
49
Mottet
,
C.
,
H. H.
Uhlig
,
F.
Powrie
.
2003
.
Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells.
J. Immunol.
170
:
3939
3943
.
50
Shale
,
M.
,
C.
Schiering
,
F.
Powrie
.
2013
.
CD4(+) T-cell subsets in intestinal inflammation.
Immunol. Rev.
252
:
164
182
.
51
Ostanin
,
D. V.
,
J.
Bao
,
I.
Koboziev
,
L.
Gray
,
S. A.
Robinson-Jackson
,
M.
Kosloski-Davidson
,
V. H.
Price
,
M. B.
Grisham
.
2009
.
T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade.
Am. J. Physiol. Gastrointest. Liver Physiol.
296
:
G135
G146
.
52
Korn
,
T.
,
M.
Mitsdoerffer
,
A. L.
Croxford
,
A.
Awasthi
,
V. A.
Dardalhon
,
G.
Galileos
,
P.
Vollmar
,
G. L.
Stritesky
,
M. H.
Kaplan
,
A.
Waisman
, et al
.
2008
.
IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells.
Proc. Natl. Acad. Sci. USA
105
:
18460
18465
.
53
Mangan
,
P. R.
,
L. E.
Harrington
,
D. B.
O’Quinn
,
W. S.
Helms
,
D. C.
Bullard
,
C. O.
Elson
,
R. D.
Hatton
,
S. M.
Wahl
,
T. R.
Schoeb
,
C. T.
Weaver
.
2006
.
Transforming growth factor-beta induces development of the T(H)17 lineage.
Nature
441
:
231
234
.
54
Gay
,
N. J.
,
M. F.
Symmons
,
M.
Gangloff
,
C. E.
Bryant
.
2014
.
Assembly and localization of Toll-like receptor signalling complexes.
Nat. Rev. Immunol.
14
:
546
558
.
55
Akira
,
S.
,
K.
Takeda
.
2004
.
Toll-like receptor signalling.
Nat. Rev. Immunol.
4
:
499
511
.
56
Lee
,
M. S.
,
Y. J.
Kim
.
2007
.
Signaling pathways downstream of pattern-recognition receptors and their cross talk.
Annu. Rev. Biochem.
76
:
447
480
.
57
Lacroix
,
M.
,
F.
Rousseau
,
F.
Guilhot
,
P.
Malinge
,
G.
Magistrelli
,
S.
Herren
,
S. A.
Jones
,
G. W.
Jones
,
J.
Scheller
,
R.
Lissilaa
, et al
.
2015
.
Novel insights into interleukin 6 (IL-6) Cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex.
J. Biol. Chem.
290
:
26943
26953
.
58
Miyahara
,
S.
,
T.
Komori
,
R.
Fujiwara
,
K.
Shizuya
,
M.
Yamamoto
,
M.
Ohmori
,
Y.
Okazaki
.
2000
.
Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain.
Life Sci.
66
:
PL93
PL98
.
59
Nowell
,
M. A.
,
A. S.
Williams
,
S. A.
Carty
,
J.
Scheller
,
A. J.
Hayes
,
G. W.
Jones
,
P. J.
Richards
,
S.
Slinn
,
M.
Ernst
,
B. J.
Jenkins
, et al
.
2009
.
Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis.
J. Immunol.
182
:
613
622
.
60
Chung
,
Y.
,
S. H.
Chang
,
G. J.
Martinez
,
X. O.
Yang
,
R.
Nurieva
,
H. S.
Kang
,
L.
Ma
,
S. S.
Watowich
,
A. M.
Jetten
,
Q.
Tian
,
C.
Dong
.
2009
.
Critical regulation of early Th17 cell differentiation by interleukin-1 signaling.
Immunity
30
:
576
587
.
61
Sarra
,
M.
,
F.
Pallone
,
T. T.
Macdonald
,
G.
Monteleone
.
2010
.
IL-23/IL-17 axis in IBD.
Inflamm. Bowel Dis.
16
:
1808
1813
.

The authors have no financial conflicts of interest.

Supplementary data